Randomized, double-blind trial of long-chain polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm infants
Fewtrell MS, Abbott RA, Kennedy K, Singhal A, Morley R, Caine E, Jamieson C, Cockburn F, Lucas A
The Journal of pediatrics · 106 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2004-04-01 · J Pediatr · vol. 144 · número 4 · págs. 471–479
- Editorial
- Elsevier BV
- Citado
- 180 citas · más que el 97% de estudios similares · 7.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 22 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Infant Nutrition and Health · Infant Development and Preterm Care
- Palabras clave
- long-chain polyunsaturated fatty acids, preterm infants, fish oil, borage oil, gamma-linolenic acid, docosahexaenoic acid, brain development, infant formula supplementation, infant growth, sex differences, Bayley Scales of Infant Development, weight gain, length gain
- MeSH
- milk, human, humans, weight gain, docosahexaenoic acids, eicosapentaenoic acid, gamma-linolenic acid, body height, double-blind method, cognition, psychomotor performance, sex factors, infant formula, infant, infant, newborn, infant, premature, female, male, infant nutritional physiological phenomena
9 autores
- Mary S. Fewtrell🇦🇺🇬🇧 · autor de correspondenciaThe University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute; University College London; Medical Research Council
- Rebecca Anne Abbott🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Kathy Kennedy🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Atul Singhal🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Ruth Morley🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Eleanor Caine🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Cherry Jamieson🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Forrester Cockburn🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
- Alan Lucas🇦🇺🇬🇧The University of Melbourne; Royal Hospital for Children; Murdoch Children's Research Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To test the efficacy and safety of long-chain polyunsaturated fatty acid (LCPUFA) supplementation with gamma-linolenic acid, a precursor of arachidonic acid, and docosahexaenoic acid in preterm infants.
Study design
Preterm (<35 weeks, < or =2000 g birth weight) infants (n=238) randomly assigned to unsupplemented or LCPUFA-supplemented formula to 9 months after term. The main outcome measure was the Bayley Mental and Psychomotor Indexes (MDI, PDI) at 18 months after term. Safety outcome measures were anthropometry (9 and 18 months), feed tolerance, infection, and clinical complications.
Results
There were no significant differences in neurodevelopment between groups overall. In preplanned subgroup analyses, LCPUFA-supplemented boys had significantly higher Bayley MDI than did control boys (difference, 5.7 points; 95% CI, 0.3 to 11.1; P=.04). LCPUFA-supplemented infants showed significantly greater weight gain (difference, 310 g; 95% CI, 30 to 590 g; P=.03) and length gain (difference, 1.0 cm; 95% CI, 0.02 to 1.9; P=.05) between birth and 9 months, with greater effect in boys (weight difference at 9 months, 510 g; 95% CI, 80 to 930 g; P=.02; length difference at 18 months, 1.8 cm; 95% CI, 0.1 to 1.8; P=.03).
Conclusions
This trial, using the strategy of providing gamma-linolenic acid as a source of arachidonic acid, showed efficacy for growth and for neurodevelopment in boys, with no adverse effects. These data have important implications for LCPUFA-supplementation strategy in preterm infants.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.